Justin Rheem, MD
Internal Medicine · Los Angeles, CANPI 1205246113
Payments from drug & device makers
Across 636 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Amgen$1K
- AbbVie$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$709
- plus $5K from 31 others
What the payments were for
- Food & beverage$11,20698%
- Education$1461%
- Gifts$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 116 | $1,436 |
| Amgen | 60 | $1,283 |
| AbbVie(2 entities) | 69 | $1,266 |
| AstraZeneca | 57 | $1,161 |
| Lilly USA, LLC | 52 | $1,029 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $709 |
| GSK | 32 | $553 |
| Novo Nordisk | 24 | $522 |
| Ironwood Pharmaceuticals, Inc | 34 | $493 |
| Boehringer Ingelheim | 13 | $291 |
| Mannkind Corporation | 15 | $271 |
| Nestle Healthcare Nutrition Inc. | 11 | $243 |
| Ardelyx, Inc. | 7 | $214 |
| Sumitomo Pharma America, Inc. | 7 | $184 |
| Otsuka America Pharmaceutical, Inc. | 7 | $174 |
| Xeris Pharmaceuticals, Inc. | 9 | $171 |
| Bayer | 8 | $158 |
| Phathom Pharmaceuticals, Inc. | 7 | $134 |
| Novartis | 6 | $130 |
| Esperion Therapeutics, Inc. | 7 | $120 |
| Braintree Laboratories, Inc. | 6 | $119 |
| Exact Sciences | 4 | $92 |
| Dexcom, Inc. | 3 | $77 |
| Merck | 4 | $73 |
| Lundbeck LLC | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Vivus LLC | 3 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $54 |
| Genentech USA, Inc. | 3 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $49 |
| Corium, LLC | 2 | $46 |
| Pfizer | 2 | $41 |
| Alfasigma USA, Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Abbott | 1 | $13 |
How this compares
$11,426 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 309 | $391,615 |
| JardianceEmpagliflozin | 436 | $315,295 |
| TrulicityDulaglutide | 245 | $289,614 |
| FarxigaDapagliflozin Propanediol | 280 | $222,276 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 84 | $203,071 |
| ZenpepLipase/Protease/Amylase | 84 | $183,456 |
| TradjentaLinagliptin | 254 | $161,232 |
| LinzessLinaclotide | 245 | $152,808 |
| OzempicSemaglutide | 153 | $150,251 |
| JanuviaSitagliptin Phosphate | 221 | $147,632 |
| VascepaIcosapent Ethyl | 456 | $135,485 |
| MyrbetriqMirabegron | 196 | $94,483 |
| ProliaDenosumab | 52 | $87,352 |
| Repatha SureclickEvolocumab | 125 | $77,382 |
| EliquisApixaban | 86 | $57,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,266 | $544,423554 claims |
| Boehringer IngelheimJardiance, Tradjenta | $291 | $476,526690 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,029 | $325,954268 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,283 | $290,422136 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,161 | $273,378372 claims |
| Novo NordiskOzempic, Rybelsus | $522 | $199,648182 claims |
| MerckJanuvia, Janumet | $73 | $191,369300 claims |
| Aimmune Therapeutics, Inc.Zenpep | $54 | $183,45684 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $94,483196 claims |
| PfizerEliquis | $41 | $57,70786 claims |
| Mannkind CorporationAfrezza | $271 | $56,16160 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $184 | $49,10976 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.